NBIX - Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data

2024-04-25 18:28:44 ET

Summary

• Neurocrine Biosciences, Inc. achieved positive results achieved from phase 2 SAVITRI study using NBI-1065845 for the treatment of patients with Major Depressive Disorder.
• NBI-1065845 may offer some advantages over currently approved MDD therapies, such as Auvelity from Axsome Therapeutics and Spravato from Johnson & Johnson.
• The global Major Depressive Disorder treatment market is expected to reach $14.96 billion by 2032.
• NBI-1070770 is another drug being advanced in the pipeline, which holds potential to target 1st-line Major Depressive Disorder patients.

Neurocrine Biosciences, Inc. ( NBIX ) was able to report positive results from its phase 2 SAVITRI study, which used a drug known as NBI-1065845 for the treatment of patients with major depressive disorder [MDD]. This drug is being advanced for the treatment of this patient population in collaboration with Takeda Pharmaceuticals ( TAK )....

For further details see: